Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
NCT07304154Phase 1Recruiting
- Sponsor
- Kite Pharma
- Start
- Apr 2026
- Primary completion
- Jun 2029
- Modality
- CAR-T Cells
- Countries
- 3
01
Overview
Phase 1, open-label trial of KITE-363 in multiple sclerosis (MS), myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) (3 arms), sponsored by Kite Pharma. Primary endpoints: Treatment-emergent Adverse Events at 3 years, Dose-limiting Toxicities at 28 days and 5 more. Started Apr 2026; status: recruiting.
02
Drugs
KITE-363
03
Conditions
multiple sclerosis (MS)myasthenia gravis (MG)chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT07304154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07304154.